Head of Global R&D, President of SYBUSA
Biopharmaceutical Division/ Samayng Holdings Inc.
Seongnam-si, Kyonggi-do, Republic of Korea
Helen Cho, PhD, studied Biochemistry at Yonsei University and Biological Engineering at the Korea Advanced Institute of Science and Technology. Under the tutelage of Dr. Danny Reinberg at the University of Medicine and Dentistry of New Jersey, she researched mRNA transcriptional regulation. As a postdoctoral trainee, she conducted research on mRNA transcriptional regulation mechanisms involved in nuclear hormone receptor signaling through epigenetic and post-transcriptional protein modifications at the Salk Institute for Biological Sciences with Dr. Ron Evans. Subsequently, Dr. Cho joined Pfizer, where she applied her multidisciplinary knowledge to develop antigen delivery platforms employing nucleic acid and viral vectors for cancer vaccine applications. As the program director of cancer vaccine programs, she led the research and development of cancer vaccine-based and oncolytic virus-based immune-oncology combination therapies into early-phase clinical trials. Recently, Dr. Cho returned to Korea and joined Samyang Holdings Corporation as the Head of R&D, where she oversees research on the application of proprietary biodegradable polymers in surgical care and medical aesthetics, nano-polymeric drug delivery system technology for oncology products, and Stability Enhanced NanoShell (SENS), a proprietary gene delivery platform for nucleic acid-based therapeutics.
Disclosure information not submitted.
Gene Delivery and Gene Editing I
Tuesday, July 9, 2024
3:30 PM - 5:30 PM CET
